This function is consistent with the inhibitory activity exerted on the non-canonical NF-kB pathway, which is active in the CLL cells and enhanced by BIRC3 deficiency (Fig. 3). Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.